The study also reviews the great potential of mRNA vaccines to treat influenza, RSV, cancer, and autoimmune diseases.

The review draws the formal regulatory distinction: gene therapy involves the deliberate and permanent alteration of a patient's genome. mRNA vaccines do not ...

Detailed price information for Aethlon Medical (AEMD-Q) from The Globe and Mail including charting and trades.

Smaller doses of COVID-19 booster vaccines can provide long-lasting immunity, helping reduce costs and improve access to ...

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.

Moderna has unveiled its first in vivo CAR-T program. Building on other groups’ ex vivo CAR-T data, the company plans to start clinical development of an off-the-shelf autoimmune disease prospect, ...

VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...

Moderna, Inc. started 2026 on a high note and is now fluctuating around a resistance zone, +2σ band formed from the VWAP. One of the reasons for the bullish sentiment around MRNA over the past three ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Among all the awards and mementos Moderna ...

Highlights validation of T-cell engager modality with mRNA-2808 in multiple myeloma, supporting rapid advancement of second T-cell engager mRNA-2151 in ovarian cancer Introduces in vivo CAR-T modality ...

Moderna (MRNA) shares surged nearly ~15% on Friday to around ~$69 and are now up almost ~42% over the past month. The Moderna stock rally came after the company shared a major business update on its ...